- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07652346
The Impact of Qualia Vitamin C+ on Individuals With Suboptimal and Adequate Vitamin C Levels
2026년 6월 10일 업데이트: Qualia Life Sciences
This is a randomized, double-blind, placebo-controlled, parallel-group, study evaluating the effect of a Qualia Vitamin C+ formulation on Whole Blood Vitamin C levels in the blood of healthy adults aged 25 years or older that have suboptimal vitamin C blood levels (i.e., 0.4 - 0.9 mg/dL) and those with adequate vitamin C blood levels (≥0.9 mg/dL).
Approximately 152 (76 in the suboptimal stratum and 76 in the adequate stratum) participants will be randomized to one of two study arms: Qualia Vitamin C+ or placebo.
Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period.
The primary outcome is the change in blood vitamin C levels in the suboptimal stratum, assessed via lab blood collection at baseline and study completion.
Secondary endpoints include the change in blood vitamin C levels, assessed via lab blood collection at baseline and study completion in the entire group, questionnaires measuring health-related Quality of Life and fatigue (RAND-36 and the FACIT-Fatigue Scale), the Single-item Assessment of Immune Fitness, evaluation of safety and tolerability, and an Overall Experience Questionnaire.
Further, a sub-group analysis of fatigued participants meeting at least mild to moderate fatigue as measured by the FACIT-Fatigue will be a secondary objective.
The NCI Fruits and Vegetable Screener - All-Day Screener will also be used to assess intake at baseline and study completion.
All assessments, including electronic questionnaires, are completed remotely without in-person visits.
연구 개요
상태
아직 모집하지 않음
상세 설명
Design: Randomized Double-Blind Placebo-Controlled Parallel 4-Armed Trial (4 arms) with 1:1:1:1 allocation, stratified by gender, age, and baseline vitamin C levels.
Arms: (1) Suboptimal Qualia Vitamin C+, (2) Suboptimal Placebo, (3) Adequate Qualia Vitamin C+, and (4) Adequate Placebo.
Participants will be stratified by gender and age at screening before being randomly assigned in a 1:1:1:1 ratio to one of the two study arms per stratum.
Each participant will take two capsules of their assigned product daily in the morning, with or without food, for 28 consecutive days.
Participants will receive a 28-day supply (56 capsules) of their assigned intervention.
The active product Qualia Vitamin C+ delivers 500 mg total vitamin C per daily serving (2 capsules) and contains a blend of Vitamin C (from liposomal vitamin C, mineral ascorbates, and fruit extracts), bioflavonoids, and ferulic acid.
The placebo contains inert rice powder in a vegetable/cellulose capsule.
Blood vitamin C levels will be measured via blood draws through Ulta Labs, which uses licensed blood draw centers operated by Quest Diagnostics.
To maintain double-blinding, a designated Qualia Life Sciences staff member independent of the research team will assign and label all study products as A or B. Both participants and study personnel will remain blinded to group assignments until study completion.
The primary analysis will be ANCOVA on Day 28 serum vitamin C in the suboptimal stratum, with baseline serum vitamin C, age, and sex as covariates and treatment arm as the factor of interest.
Total enrollment: 152.
연구 유형
중재적
등록 (추정된)
152
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Colin Gardner, PhD
- 전화번호: 678-387-7924
- 이메일: colin@qualialife.com
연구 연락처 백업
- 이름: Abhimanyu Ardagh
- 전화번호: 530-263-4469
- 이메일: abhi@qualialife.com
연구 장소
-
-
California
-
Carlsbad, California, 미국, 92008
- Qualia Life Sciences
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
예
설명
Inclusion Criteria:
- Provide voluntary, written, informed consent to participate in the study.
- Agree to provide a valid cell phone number and are willing to receive communications through text.
- Can read and write English.
- Willing to complete questionnaires, records, and diaries associated with the study.
- Healthy male and female participants aged 25 to 75 years old.
- Willing to go to an Ulta Labs Patient Service Center location for a Blood Vitamin C Test (baseline and Day 29) and located within a convenient distance of participating locations. The services offered by Ulta Lab Tests are available only in the United States and not to residents of the states of New Jersey, New York, and Rhode Island.
- Willing to avoid starting new or stopping any existing dietary supplements throughout the study.
- Willing to maintain a consistent diet throughout the study.
Exclusion Criteria:
- Women who are pregnant, breastfeeding, or planning to become pregnant or start breastfeeding during the trial.
- Known food intolerances/allergy to any ingredients in the product.
- Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer.
- Having had a significant cardiovascular event in the past 6 months.
- Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines.
- On immunosuppressive therapy.
- Adults lacking capacity to consent.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Suboptimal Qualia Vitamin C+
Participants with suboptimal vitamin C blood levels (0.4 - 0.9 mg/dL) taking two capsules of Qualia Vitamin C+ once daily in the morning, with or without food, for 28 days.
38 participants.
|
A novel multi-ingredient formulation delivering 500 mg total vitamin C per daily serving (2 capsules).
It contains a blend of Vitamin C (from liposomal vitamin C, mineral ascorbates, and fruit extracts), bioflavonoids, and ferulic acid.
Participants take two capsules daily in the morning, with or without food, for 28 consecutive days.
|
|
위약 비교기: Suboptimal Placebo
Participants with suboptimal vitamin C blood levels (0.4 - 0.9 mg/dL) taking two capsules of placebo (inert rice powder in a vegetable/cellulose capsule) once daily in the morning, with or without food, for 28 days.
38 participants.
|
Contains inert rice powder in a vegetable/cellulose capsule.
Participants take two capsules daily in the morning, with or without food, for 28 consecutive days.
|
|
실험적: Adequate Qualia Vitamin C+
Participants with adequate vitamin C blood levels (≥0.9 mg/dL) taking two capsules of Qualia Vitamin C+ once daily in the morning, with or without food, for 28 days.
38 participants.
|
A novel multi-ingredient formulation delivering 500 mg total vitamin C per daily serving (2 capsules).
It contains a blend of Vitamin C (from liposomal vitamin C, mineral ascorbates, and fruit extracts), bioflavonoids, and ferulic acid.
Participants take two capsules daily in the morning, with or without food, for 28 consecutive days.
|
|
위약 비교기: Adequate Placebo
Participants with adequate vitamin C blood levels (≥0.9 mg/dL) taking two capsules of placebo (inert rice powder in a vegetable/cellulose capsule) once daily in the morning, with or without food, for 28 days.
38 participants.
|
Contains inert rice powder in a vegetable/cellulose capsule.
Participants take two capsules daily in the morning, with or without food, for 28 consecutive days.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in blood Vitamin C levels in the suboptimal stratum
기간: Baseline to Day 28
|
To assess between-group differences in the change in blood Vitamin C levels in the suboptimal stratum from baseline to Day 28 following supplementation with Qualia Vitamin C+ versus placebo.
Assessed via Ulta Labs Vitamin C Test (lab blood collection).
|
Baseline to Day 28
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in blood Vitamin C levels in the entire cohort
기간: Baseline to Day 28
|
To assess between-group differences in the change in blood Vitamin C levels in the entire cohort from baseline to Day 28 following supplementation with Qualia Vitamin C+ versus placebo.
|
Baseline to Day 28
|
|
FACIT-Fatigue Scale
기간: Baseline to Day 28
|
To assess within-group and between-group differences in the FACIT-Fatigue Scale in both the sub-optimal vitamin C stratum and the entire cohort.
Final score ranges from 0 to 52, where higher scores indicate less fatigue and better quality of life.
|
Baseline to Day 28
|
|
RAND-36
기간: Baseline to Day 28
|
To assess within-group and between-group differences in the RAND-36 (primary attention to the Vitality, General Health Perceptions, and Physical Functioning subscales) in both the sub-optimal vitamin C stratum and the entire cohort.
Each domain is scored on a 0-100 scale, with higher scores indicating better health.
|
Baseline to Day 28
|
|
Single-item Assessment of Immune Fitness
기간: Baseline to Day 28
|
To assess within-group and between-group differences in the Single-item Assessment of Immune Fitness in both the sub-optimal vitamin C stratum and the entire cohort.
A single numerical score between 0 and 10 is produced, with higher scores indicating better self-rated immune fitness.
|
Baseline to Day 28
|
|
Within-group change in blood Vitamin C levels
기간: Baseline to Day 28
|
To assess within-group differences in the change in blood Vitamin C levels in both the suboptimal stratum and entire cohort.
|
Baseline to Day 28
|
|
Proportion of suboptimal group achieving status normalization
기간: Week 4
|
To estimate the proportion of the suboptimal group participants achieving plasma vitamin C (≥0.9 mg/dL; i.e., 'status normalization') at Week 4.
|
Week 4
|
|
Safety and Tolerability survey
기간: Baseline, Day 7, Day 14, Day 21, and Day 28
|
To evaluate side effect profiles using a custom Safety and Tolerability survey.
|
Baseline, Day 7, Day 14, Day 21, and Day 28
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Experience Questionnaire
기간: 5-7 days after final dose (Day 34-36)
|
Captures information that may be used for product evaluation and marketing, asked 5-7 days after the final dose of the test product.
|
5-7 days after final dose (Day 34-36)
|
|
NCI Fruits and Vegetable Screener - All-Day Screener
기간: Baseline and Day 28
|
Used to assess fruit and vegetable intake at baseline and study completion, for statistical control purposes only.
|
Baseline and Day 28
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 수석 연구원: William Scuba, Qualia Life Sciences
- 수석 연구원: Colin Gardner, PhD, Qualia Life Sciences
- 수석 연구원: Sarah Blomquist, PhD, Qualia Life Sciences
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2026년 7월 1일
기본 완료 (추정된)
2026년 11월 1일
연구 완료 (추정된)
2026년 12월 1일
연구 등록 날짜
최초 제출
2026년 6월 10일
QC 기준을 충족하는 최초 제출
2026년 6월 10일
처음 게시됨 (실제)
2026년 6월 17일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 6월 17일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 6월 10일
마지막으로 확인됨
2026년 6월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- QLS-023
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Qualia Vitamin C+에 대한 임상 시험
-
Haukeland University HospitalNorwegian Foundation for Health and Rehabilitation; Foundation to Promote Research into...완전한
-
Haukeland University HospitalNorwegian Foundation for Health and Rehabilitation; Foundation to Promote Research into...완전한